These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 20022944)

  • 1. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
    Monsey J; Shen W; Schlesinger P; Bose R
    J Biol Chem; 2010 Mar; 285(10):7035-44. PubMed ID: 20022944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways.
    Choi BK; Cai X; Yuan B; Huang Z; Fan X; Deng H; Zhang N; An Z
    Protein Cell; 2012 Oct; 3(10):781-9. PubMed ID: 22983903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
    Jura N; Shan Y; Cao X; Shaw DE; Kuriyan J
    Proc Natl Acad Sci U S A; 2009 Dec; 106(51):21608-13. PubMed ID: 20007378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.
    Littlefield P; Liu L; Mysore V; Shan Y; Shaw DE; Jura N
    Sci Signal; 2014 Dec; 7(354):ra114. PubMed ID: 25468994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.
    Collier TS; Diraviyam K; Monsey J; Shen W; Sept D; Bose R
    J Biol Chem; 2013 Aug; 288(35):25254-25264. PubMed ID: 23843458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
    Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
    Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
    J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
    Aertgeerts K; Skene R; Yano J; Sang BC; Zou H; Snell G; Jennings A; Iwamoto K; Habuka N; Hirokawa A; Ishikawa T; Tanaka T; Miki H; Ohta Y; Sogabe S
    J Biol Chem; 2011 May; 286(21):18756-65. PubMed ID: 21454582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
    Kong A; Calleja V; Leboucher P; Harris A; Parker PJ; Larijani B
    PLoS One; 2008 Aug; 3(8):e2881. PubMed ID: 18682844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.
    Shih AJ; Telesco SE; Choi SH; Lemmon MA; Radhakrishnan R
    Biochem J; 2011 Jun; 436(2):241-51. PubMed ID: 21426301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single ligand is sufficient to activate EGFR dimers.
    Liu P; Cleveland TE; Bouyain S; Byrne PO; Longo PA; Leahy DJ
    Proc Natl Acad Sci U S A; 2012 Jul; 109(27):10861-6. PubMed ID: 22699492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
    Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
    Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
    Shankaran H; Zhang Y; Tan Y; Resat H
    PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.
    Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G
    J Transl Med; 2015 May; 13():171. PubMed ID: 26021752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family.
    Arkhipov A; Shan Y; Kim ET; Dror RO; Shaw DE
    Elife; 2013 Jul; 2():e00708. PubMed ID: 23878723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.
    Banappagari S; Corti M; Pincus S; Satyanarayanajois S
    J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
    Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
    Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.